Abstracts

Pregabalin Adverse Events Analysis Using Propensity Score Matching

Abstract number : 2.405
Submission category : 7. Anti-seizure Medications / 7D. Drug Side Effects
Year : 2024
Submission ID : 519
Source : www.aesnet.org
Presentation date : 12/8/2024 12:00:00 AM
Published date :

Authors :
Presenting Author: Hyeyeon Chang, MD, PhD – Konyang Univ. Hospital

Tae-Joon Kim, M.D., Ph.D. – Aju Univ hospital
Yong-Won Shin, MD, PhD – Seoul National University Hospital
Dooyeon Jang, M.S. – Seoul Nation University
Jeeyoung Hong, Ph.D. – Konyang University Medical Center
Kyung-Il Park, MD, PhD – Seoul National University Hospital
Kon Chu, MD, PhD – Seoul National University Hospital
Sang Kun Lee, MD, PhD – Seoul National University Hospital

Rationale: Pregabalin acts as a high-affinity ligand for the α2δ subunit of voltage-dependent calcium channels and is a second-generation antiseizure medication (ASM). Pregabalin has linear and predictable pharmacokinetic properties with almost complete renal excretion. Due to these characteristics, pregabalin has minimal interaction with other drugs. Pregabalin is seldom used as monotherapy because it is an adjunctive medication for epilepsy. Therefore, it is crucial to identify adverse events when combined with other ASMs. Paradoxically, because of simple PK traits, the combined effects of this ASM with other antiseizure medications are not fully understood. In this report, we aimed to identify the characteristics of adverse events for each antiseizure medication when used with PGB and examine the differences in PGB adverse events using propensity score matching.


Methods: From a cohort of 2963 epilepsy patients at seoul National University Hospital we identified 325 who took PGB and selected 149 for study after demographic filtering. We also designated 968 control patients from those who didn’t take PGB. Using Propensity Score Matching (PSM), we performed logistic regression to calculate the probability of belonging to the PGB group and matched subjects at a 1:1 ratio. This process was repeated ten times. We then compared the occurrence of adverse events (AEs) in three ways to differentiate whether AEs were caused by each CoASM or the combination of CoASM and PGB.


Results: We used propensity score matching (PSM) to compare 149 patients who received pregabalin (PGB) with 149 control patients who did not. PGB was associated with higher rates of somnolence, dizziness, and other adverse events (AEs) than the control group (p< 0.05). We also compared PGB with each co-antiseizure medication (CoASM) in the control group using PSM. PGB had higher rates of somnolence than all CoASMs, and higher rates of dizziness and other AEs than some CoASMs (p< 0.05). We further analyzed the data to minimize the effects of CoASMs on AEs. We found that somnolence was a consistent AE of PGB, while dizziness and other AEs were influenced by the interaction between PGB and CoASMs.


Conclusions: We clarified the differences in adverse events between the group using PGB and other antiseizure medications using PSM. These results will help clinicians make decisions regarding the use of antiseizure medications.


Funding: None.

Anti-seizure Medications